SynthesisAdvances in therapy2025

Pembrolizumab with Carboplatin and Paclitaxel Versus Alternative Systemic Treatments Recommended for the First-Line Treatment of Recurrent/Metastatic Head and Neck Cancer: An Indirect Treatment Comparison.

Marcin Dzienis et al.PubMed ↗Publisher ↗

No numbers read from the abstract.